glp 1 glucagon Glucagon-like peptide (GLP-1) GLP-1/glucagon receptor co-agonism for treatment

In a Phase 2b study in people with type 2 diabetes and obesity over 54 weeks, treatment with cotadutide at doses of 100-300 g daily improved some non-invasive markers of NAFLD such as transaminase levels, the FIB-4 index, fatty liver disease fibrosis score (NFS) and fatty liver index (FLI) but fatty liver disease was not assessed directly with liver biopsy

The World Health Organisation (WHO) is now considering recommending them in their global guidelines as essential treatments for diabetes and obesity care

Service providers and contract development and manufacturing organizations (CDMOs) are also very crucial actors in the ecosystem of obesity drugs

Pickford, S

These medications are complex peptides that must be injected to enter the bloodstream effectively